SBIR-STTR Award

Single-Molecule Analyte Detection by Molecular Motor-driven Nanodevices
Award last edited on: 3/3/2022

Sponsored Program
STTR
Awarding Agency
NIH : NIGMS
Total Award Amount
$149,265
Award Phase
1
Solicitation Topic Code
NIGMS
Principal Investigator
Wayne D Frasch

Company Information

Attometrics LLC

15013 South 24th Way
Phoenix, AZ 85048
   (480) 759-7001
   N/A
   www.biomarker-diagnostics.com

Research Institution

----------

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2016
Phase I Amount
$149,265
?There is an urgent need for a platform technology that can monitor changes in metabolite and protein biomarkers below current detection limits because, in many cases, the disease has progressed to an advanced state by the time the abundance of the biomarker has become measurable. Our molecular motor-powered nanodevice-linked immunosorbent assay (MONA- LISA) is capable of detecting the presence of as few as ~3 molecules of target Hsp70 protein, a cancer biomarker, with a large linear dynamic detection range. Through an innovative use of the CAP transcriptional regulatory protein, our MONA-based nanodevices can now detect the presence of the metabolite cAMP, which is also a cancer biomarker. We now plan to determine the dynamic range of and detection limit of cAMP. We also plan to enable MONA devices to detect NAD+/NADH ratios. Since we have previously demonstrated the ability of MONA to detect target DNA sequences, MONA represents a powerful platform technology capable of detecting proteins, metabolites and DNA with a single instrument, which is unique among molecular detection technologies.

Public Health Relevance Statement:


Public Health Relevance:
There is an urgent need for a platform technology that can monitor changes in metabolite and protein biomarkers below current detection limits because, in many cases, the disease has progressed to an advanced state by the time the abundance of the biomarker has become measurable. Our molecular motor-powered nanodevice-linked immunosorbent assay (MONA- LISA) is capable of detecting the presence of as few as ~3 molecules of the cancer biomarker protein Hsp70 as well as DNA targets. Through an innovative adaptation, we can now detect the metabolite cAMP, which is also a cancer biomarker. Expanding the metabolite detection capabilities of MONA will provide a powerful platform technology capable of detecting proteins, metabolites and DNA with a single instrument, which is unique among molecular detection technologies.

NIH Spending Category:
Bioengineering; Nanotechnology

Project Terms:
Adopted; base; Binding; Binding Proteins; Biological Assay; Biological Markers; cancer biomarkers; crosslink; Cyclic AMP; Detection; Devices; Diazomethane; Disease; Dissociation; DNA; DNA Sequence; Docking; ds-DNA; Event; Immunosorbents; innovation; instrument; Link; Measurable; Measurement; Molecular; Molecular Conformation; Molecular Motors; Monitor; Motor; NADH; nanodevice; nanorod; Oxidation-Reduction; prevent; protein biomarkers; protein metabolite; Proteins; public health relevance; Repressor Proteins; research study; Sampling; Signal Transduction; single molecule; Technology; Testing; Time; Transcription Regulatory Protein

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----